- Home
- JLL vs BAX Comparison
JLL vs BAX Comparison
Compare JLL & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- BAX
- Stock Information
- Founded
- JLL 1997
- BAX 1931
- Country
- JLL United States
- BAX United States
- Employees
- JLL N/A
- BAX N/A
- Industry
- JLL Real Estate
- BAX Medical/Dental Instruments
- Sector
- JLL Finance
- BAX Health Care
- Exchange
- JLL Nasdaq
- BAX Nasdaq
- Market Cap
- JLL 13.1B
- BAX 15.6B
- IPO Year
- JLL 1997
- BAX N/A
- Fundamental
- Price
- JLL $259.56
- BAX $33.46
- Analyst Decision
- JLL Strong Buy
- BAX Buy
- Analyst Count
- JLL 7
- BAX 9
- Target Price
- JLL $309.00
- BAX $38.56
- AVG Volume (30 Days)
- JLL 379.3K
- BAX 4.4M
- Earning Date
- JLL 05-05-2025
- BAX 05-01-2025
- Dividend Yield
- JLL N/A
- BAX 2.06%
- EPS Growth
- JLL 141.97
- BAX N/A
- EPS
- JLL 11.30
- BAX N/A
- Revenue
- JLL $23,432,900,000.00
- BAX $10,636,000,000.00
- Revenue This Year
- JLL $11.66
- BAX $6.13
- Revenue Next Year
- JLL $7.30
- BAX $4.12
- P/E Ratio
- JLL $23.01
- BAX N/A
- Revenue Growth
- JLL 12.87
- BAX 2.66
- 52 Week Low
- JLL $171.45
- BAX $28.34
- 52 Week High
- JLL $288.50
- BAX $43.99
- Technical
- Relative Strength Index (RSI)
- JLL 50.22
- BAX 47.17
- Support Level
- JLL $246.90
- BAX $33.00
- Resistance Level
- JLL $256.38
- BAX $35.03
- Average True Range (ATR)
- JLL 8.56
- BAX 0.88
- MACD
- JLL 1.20
- BAX -0.35
- Stochastic Oscillator
- JLL 68.07
- BAX 12.82
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.